Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H-Ras antisense oligodeoxynucleotide ISIS 2503
- Development stage
- Phase 2
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
ISIS 2503 is a synthetic, 20-base phosphorothioate antisense oligodeoxynucleotide designed to hybridize to the translation initiation region of human H-Ras mRNA. By binding specifically to this sequence, it selectively inhibits the expression of H-Ras, an oncogene implicated in the development and maintenance of various cancers. This targeted inhibition may suppress tumor cell growth in Ras-dependent tumors while sparing other members of the Ras protein family. Developed as an anti-cancer agent, ISIS 2503 has been evaluated primarily for pancreatic cancer and also investigated in metastatic breast cancer and non-small cell lung cancer. The drug was developed by Isis Pharmaceuticals (now Ionis Pharmaceuticals) and reached Phase II clinical trials[1][2][3][5][7].
- Other names
- h-ras antisense oligodeoxynucleotide isis 2503
02
Targets
HRAS (H-Ras protein)
Beyond the preview
Go deeper on H-Ras antisense oligodeoxynucleotide ISIS 2503.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H-Ras antisense oligodeoxynucleotide ISIS 2503.